Back to Search
Start Over
Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016.
- Source :
- Acta Oncologica; Jan2020, Vol. 59 Issue 1, p101-105, 5p, 1 Chart, 1 Graph
- Publication Year :
- 2020
-
Abstract
- The article describes the experience with Brentuximab vedotin (BV) antibody-drug conjugate in r/r cHL in Norway for patients treated with the approved indications from 2011 to 2016. Highlights include consolidation of responses to BV achieved through radiotherapy in isolated patients, approval of the study by the South East Regional Committee for Medical and Health Research Ethics, and comparison of patients treated with BV and a population-based historical cohort.
- Subjects :
- HODGKIN'S disease treatment
THERAPEUTIC use of monoclonal antibodies
CANCER relapse
COMBINATION drug therapy
CHI-squared test
CONFIDENCE intervals
HEMATOPOIETIC stem cell transplantation
HODGKIN'S disease
IMIDAZOLES
MONOCLONAL antibodies
POSTOPERATIVE period
TREATMENT effectiveness
RETROSPECTIVE studies
KAPLAN-Meier estimator
LOG-rank test
MANN Whitney U Test
DISEASE risk factors
Subjects
Details
- Language :
- English
- ISSN :
- 0284186X
- Volume :
- 59
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Acta Oncologica
- Publication Type :
- Academic Journal
- Accession number :
- 140466970
- Full Text :
- https://doi.org/10.1080/0284186X.2019.1652765